Biohaven initiated first-in-human Phase 1 clinical dosing for BHV-1600 in late 2024 to treat peripartum cardiomyopathy (PPCM).

Mechanism: BHV-1600 is a targeted removal of aberrant protein (TRAP) degrader designed to selectively bind and eliminate pathogenic β₁-adrenergic receptor (β₁AR) autoantibodies.